New appointment at Micromet
This article was originally published in Scrip
Micromet, a US biopharmaceutical company developing proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, has appointed Barclay Phillipssenior vice-president and chief financial officer. He has served as a member of the company's board of directors since December 2000. From 1999 to August 2008, Mr Phillips was a managing director of Vector Fund Management.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.